

ASX RELEASE

22 November 2017

## **KAZIA THERAPEUTICS – CLARIFICATION OF MEDIA REPORT**

Sydney, 22 November 2017 – Kazia Therapeutics Limited (ASX: **NRTDA**; NASDAQ: **NVGN**), formerly Novogen Limited (the Company), an Australian oncology drug development company, seeks to provide clarification to shareholders regarding a recent media report referring to Noxopharm Limited (ASX: **NOX**) and Dr Graham Kelly, who is the Managing Director and Chief Executive Officer of Noxopharm, and a former CEO of the Company.

The media report stated that NOX66 (Noxopharm's lead program) was designed by Dr Graham Kelly when he was an employee of the Company. Following the publication of that report in online media on Monday 20 November 2017, the Company has become aware of speculation among certain of its shareholders regarding the Company's intellectual property position. Accordingly, the Company considers itself obliged to provide a public statement in accordance with its continuous disclosure obligations under ASX Listing Rule 3.1.

The Company considers the protection of its intellectual property to be among its highest responsibilities to shareholders and in this regard is in ongoing discussions with both Dr Kelly and Noxopharm through the parties' respective lawyers.

For clarity, the matters under discussion with Noxopharm have no bearing on the intellectual property associated with the Company's own development programs.

**ENDS**

### **Board of Directors**

**Mr Iain Ross** Chairman, Non-Executive Director

**Mr Bryce Carmine** Non-Executive Director

**Mr Steven Coffey** Non-Executive Director

**Dr James Garner** Chief Executive Officer, Managing Director

## About Kazia Therapeutics Limited

Kazia Therapeutics Limited, formerly Novogen Limited (ASX: NRTDA, NASDAQ: KZIA) is an agile oncology-focused biotechnology company, based in Sydney, Australia. We have two clinical staged drug development candidates and an early stage discovery program, and are developing therapies across a range of oncology indications. The Company will trade under the following tickers over the next 2 weeks:

### ASX

- Currently: ordinary shares as NRTDA, options as NRTDB
- On 28 November: ordinary shares as NRT, options as NRTO
- From 29 November: ordinary shares as KZA, options as KZAO

### NASDAQ

- Currently NVGN
- From 24 November: KZIA

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017.

TRXE-002-1, or Cantrixil is Kazia's second drug development candidate under development as a treatment for ovarian cancer. The chemotherapeutic is currently undergoing a Phase I clinical trial in hospitals across Australia and the United States. Initial data on this trial is expected to be reported early in 2018.